Form 4: Poplar Point Capital Partners LP Increases Stake in NovaBay Pharmaceuticals

Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals common stock between March 18 and March 25, 2025, increasing their holdings to 868,204 shares.

Summary

• Poplar Point Capital Partners LP, Poplar Point Capital Management LLC, Poplar Point Capital GP LLC, and Jad Fakhry jointly filed a Form 4.
• The filing reports purchases of NovaBay Pharmaceuticals, Inc. common stock by Poplar Point Capital Partners LP between March 18, 2025, and March 25, 2025.
• The purchases totaled 49,927 shares at prices ranging from $0.6025 to $0.63 per share.
• Following these transactions, the reporting entities collectively beneficially own 868,204 shares of NovaBay Pharmaceuticals common stock.
• Jad Fakhry is the manager of Poplar Point Capital Management LLC and Poplar Point Capital GP LLC and owns a controlling interest in these entities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock purchases. The increased stake could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• The increased stake by Poplar Point Capital Partners LP could be interpreted as a sign of confidence in NovaBay Pharmaceuticals' future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. These filings provide transparency into the trading activities of those with privileged information.

Stakeholder Impact

• The increased ownership by Poplar Point Capital Partners LP could potentially reassure shareholders.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Partners, Jad Fakhry, Form 4, Beneficial Ownership, Stock Acquisition, NBY